HP has become an option for neoadjuvant and adjuvant postoperative adjuvant therapy in patients with HER2-positive early breast cancer ≥T2 or ≥N1 and is a standard recommendation for first-line treatment of patients with metastatic breast cancer [53]. The gene discussed is ERBB2; the disease is breast carcinoma.